Jichuang Wang
Fujian Key Laboratory Of Natural Medicine Pharmacology
Fuzhou, China
Fuzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Flavokawain A Targets CXCR4-Mediated Vasculogenic Mimicry to Reverse Hepatocellular Carcinoma Resistance to Tyrosine Kinase Inhibitors.
Journal: Phytotherapy research : PTR
Published: August 14, 2025
Corrigendum to "Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway" [Cancer Lett. 444 (2019) 82-93].
Journal: Cancer letters
Published: September 27, 2024
COL5A2 drives regorafenib resistance-induced metastatic phenotype via reducing LIFR expression in hepatocellular carcinoma.
Journal: Acta biochimica et biophysica Sinica
Published: May 31, 2024
Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies.
Journal: Pharmacological research
Published: June 23, 2022
Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma.
Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma.
Journal: Pharmacological research
Published: November 24, 2020
Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1-mediated EMT.
Journal: Molecular carcinogenesis
Published: September 21, 2020
Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Journal: Journal of experimental & clinical cancer research : CR
Published: January 24, 2019
Pin1 inhibition potently suppresses gastric cancer growth and blocks PI3K/AKT and Wnt/β-catenin oncogenic pathways.
Journal: Molecular carcinogenesis
Published: December 27, 2018
Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway.
Journal: Cancer letters
Published: September 13, 2018
CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Journal: Molecular carcinogenesis
Published: March 26, 2018
A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: August 24, 2017
Last Updated: 09/26/2026